Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771418/ |